 Home > Medical News > Medicines Company News > Renfu Pharmaceutical became powerful, grabbing Hengrui's exclusive injection that soared 137%.

Renfu Pharmaceutical became powerful, grabbing Hengrui's exclusive injection that soared 137%.

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

3 4 water

what data protection

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 29, Yichang Renfu Pharmaceutical once again submitted a Class 3 generic marketing application
for esketamine hydrochloride injection.
Esketamine hydrochloride injection is currently the exclusive product of Jiangsu Hengrui Pharmaceutical, with terminal sales of more than 170 million yuan
in public medical institutions in China in 2021.

Figure 1: Yichang Renfu Pharmaceutical's declaration of esketamine hydrochloride injection

Source: CDE official website

Jiangsu Hengrui Pharmaceutical won the first domestic imitation of esketamine hydrochloride injection in 2019, temporarily as an exclusive product, entered the national medical insurance after negotiation in 2020, and is now a negotiated variety of the 2021 version of the national medical insurance catalog, limited to the induction and implementation of general anesthesia in combination with sedative anesthetic
drugs.

Figure 2: Sales of esketamine hydrochloride injection (10,000 yuan)

Source: Minai.
com Competition Pattern of Drug Terminals in China's Public Medical Institutions

According to data from Minai.
com, in 2021, at the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions), the sales of esketamine hydrochloride injection have exceeded 170 million yuan, with a growth rate of more than 137%, and in the first half of 2022, it will continue to maintain double-digit growth, and the market potential can be expected
.

Figure 3: Clinical trial of esketamine hydrochloride injection of Yichang Renfu Pharmaceutical

Source: Minainet new version of the database

Yichang Renfu Pharmaceutical submitted a Class 3 generic marketing application for esketamine hydrochloride injection for the first time in 2020, and was finally approved for clinical trials, and its confirmatory clinical trial was completed in June this year, and the marketing application is now submitted again, which shows that the company attaches great importance to this product
.

In addition, Yangzijiang Pharmaceutical Group also submitted a type 3 generic listing application for esketamine hydrochloride injection in November this year, and we will wait
and see who can seize the second domestic throne in the end.

Figure 4: Neurological drugs approved for marketing since this year (excluding Class 2.
4)

Source: Minainet new version of the database

Since the beginning of this year, the company has approved 4 new neurological drugs, of which clobazam tablets are the first imitation in China and are temporarily exclusive products, and oxycodone hydrochloride sustained-release tablets have also become the first in China
.

Source: CDE official website, Minainet database Note: Minai.
com "Drug Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Data statistics as of December 29, if there are omissions, welcome to correct!

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.